Meeting
2016 ASCO Annual Meeting
A Markov model to evaluate cost-effectiveness of the PARP inhibitor, olaparib, for fourth line treatment of recurrent ovarian cancer.
Authors
Juliet Elizabeth Wolford
UC Irvine, Orange, CA
Juliet Elizabeth Wolford , Jiaru Bai , Ramez Hassef Eskander , Robin Keller , Lindsey Minion , John K. Chan , Bradley J. Monk , Krishnansu Sujata Tewari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5563)
DOI
10.1200/JCO.2016.34.15_suppl.5563
Abstract #
5563
Poster Bd #
386
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Evaluating the cost-effectiveness of current FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer.
First Author: Juliet Elizabeth Wolford
Poster
2022 ASCO Annual Meeting
Real-world use, tolerability, and dose modifications of PARP inhibitors in ovarian cancer.
First Author: David M. O'Malley
Poster
2022 ASCO Annual Meeting
A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.
First Author: Fabian Trillsch
Poster
2021 ASCO Quality Care Symposium
Reasons for first-line maintenance therapy discontinuation among patients with newly diagnosed advanced ovarian cancer treated in real-world settings.
First Author: Jinan Liu